查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1901484

膿皰瘡治療市場：依給藥途徑、病患類型、藥物類別、配銷通路、國家及地區分類－全球產業分析、市場規模、市場佔有率及2025-2032年預測

Impetigo Treatment Market, By Route of Administration, By Patient Type, By Drug Class, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 365 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年膿皰瘡治療市場規模為 7.78 億美元，從 2025 年到 2032 年將以 5.8% 的複合年成長率成長。

膿皰瘡治療市場涵蓋用於治療膿皰瘡的藥品、外用抗生素、消毒劑和先進的皮膚科解決方案。膿皰瘡是一種傳染性細菌性皮膚感染，主要影響兒童。與衛生條件差、人口擁擠和細菌抗藥性增強相關的皮膚感染日益普遍，是推動市場成長的主要因素。一個關鍵的市場趨勢是轉向非抗生素和消毒劑療法，這反映了全球對抗抗菌素抗藥性的努力。然而，市場面臨抗甲氧西林金黃色葡萄球菌（MRSA）感染日益增多的嚴峻挑戰，MRSA 會降低傳統抗生素的療效，並使治療方案複雜化。儘管如此，聯合療法、新型外用製劑和速效抗菌劑的創新帶來了巨大的機遇，使治療方案更具針對性且不易產生抗藥性。隨著醫療保健系統將皮膚感染控制和更有效的抗菌藥物使用放在首位，這些因素共同推動了膿皰瘡治療市場的穩定成長。

膿皰瘡治療市場－市場動態

日益重視高級皮膚病學和傳染病管理

抗生素抗藥性和皮膚感染盛行率的上升是膿皰瘡治療市場的主要促進因素。為了確保治療成功，醫療系統正在優先考慮更快速的診斷、改進的製劑和先進的抗菌解決方案。策略性的產業發展提升了研發能力，從而進一步推動了這一趨勢。例如，2020年1月，諾華收購了The Medicines Company，顯著增強了其治療產品線，並展現了該行業致力於開發傳染病解決方案的決心。儘管此次收購的重點是inclisiran，但它反映了該行業向高創新產品組合邁進的更大趨勢，間接加速了皮膚病學和皮膚感染治療（包括膿皰瘡）領域的進展。

膿皰瘡治療市場區隔分析：

全球膿皰瘡治療市場按給藥途徑、患者類型、藥物類別、配銷通路和地區進行細分。

根據給藥途徑，口服給藥在膿皰瘡治療市場中佔據重要地位，因為它對中重度感染、復發病例以及局部抗生素治療無效的情況均有效。阿莫西林-克拉維酸鉀、克林黴素和大環內酯類等口服製劑具有全身性作用，有助於消除深層或廣泛感染。抗菌藥物創新和聯合療法的不斷發展也推動了這一領域的需求。 2020年3月，Menlo Therapeutics與Foamix Pharmaceuticals的合併增強了其皮膚病產品組合，間接促進了針對膿皰瘡等皮膚疾病的抗生素和抗感染療法的研發。此類策略聯盟增強了研發能力，有助於開發更有效的口服製劑，從而推動該領域向前發展。

按配銷通路，醫院藥房管道仍然至關重要，因為醫院需要治療更多病情嚴重、傳播迅速或免疫功能低下的膿皰瘡病例，這些病例需要及時獲得經過驗證的藥物。該管道受益於規範的抗生素管理、專家會診以及先進的診斷技術。醫院皮膚科服務和疫情管理方案的增加也推動了該通路的發展。例如，2021年11月，NovaBay Pharmaceuticals收購了DERMAdoctor，擴大了該公司專注於皮膚科的產品分銷管道，包括醫院等專業管道。此類企業措施增加了醫院藥房中皮膚科醫生推薦製劑的供應，從而改善了患者獲得可靠膿皰瘡治療方案的機會。

膿皰瘡治療市場—地域性洞察

北美地區在膿皰瘡治療市場佔據主導地位，這主要歸功於細菌性皮膚感染的高發生率以及公眾（尤其是兒童）對膿皰瘡的廣泛認知。該地區擁有先進的醫療保健基礎設施、便利的皮膚科醫生資源以及完善的醫保報銷系統。此外，強而有力的政府公共衛生計畫以及品牌藥和學名藥處方藥的廣泛供應也加速了市場對膿皰瘡治療的接受度。高水準的醫療保健支出、常規臨床篩檢以及快速診斷能力都有助於早期發現並有效治療膿皰瘡病例。此外，大型製藥公司積極參與皮膚病學研發，尤其是在對抗抗生素抗藥性方面，進一步鞏固了北美地區的市場領導地位。

美國膿皰瘡治療市場—國家概況

美國是膿皰瘡治療領域最具影響力的市場之一，這得益於其完善的醫療保健基礎設施、高度的感染防範意識以及廣泛的皮膚科服務。美國細菌性皮膚感染的發生率居高不下，尤其是在兒童族群中，這推動了對局部和口服抗生素的持續需求。此外，美國重視透過常規兒科篩檢進行早期診斷，以達到及時有效的治療。強大的藥物創新能力，以及先進的研發實力和簡化的監管流程，進一步塑造了這個市場。

例如，2025年6月，賽諾菲的Dupixent（度普利尤單抗）獲得FDA批准，用於治療大皰性類天皰瘡，一種發炎性皮膚病。雖然它並非直接治療膿皰瘡，但這一里程碑事件凸顯了美國皮膚病學創新領域的蓬勃發展，為治療相關皮膚感染和改善患者長期預後開闢了新的途徑。

目錄

第1章：膿皰瘡治療市場概覽

  • 研究範圍
  • 市場估算年份

第2章：執行概要

  • 市集
  • 競爭洞察

第3章：膿皰瘡治療市場主要趨勢

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 市場未來趨勢

第4章：膿皰瘡治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景分析
  • 規範架構分析

第5章：膿皰瘡治療市場：地緣政治緊張局勢升級的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：膿皰瘡治療市場概況

  • 膿皰瘡治療市佔率分析，2024 年
  • 主要製造商細分數據
    • 知名球員分析
    • 新興參與者分析

第7章：膿皰瘡治療市場：依給藥途徑分類

  • 概述
    • 細分市場佔有率分析：按給藥途徑
    • 主題
    • 口服

第8章：膿皰瘡治療市場：依患者類型分類

  • 概述
    • 細分市場佔有率分析：按患者類型
    • 孩子們
    • 老年
    • 成年人

第9章：膿皰瘡治療市場：依藥物類別分類

  • 概述
    • 細分市場佔有率分析：依藥物類別分類
    • 頭孢菌素
    • 奎諾酮類
    • 磺胺類藥物
    • 夫西丹
    • 林可醯胺
    • 青黴素
    • 四環素
    • 其他

第10章：膿皰瘡治療市場：依配銷通路分類

  • 概述
    • 細分市場佔有率分析：按患者類型
    • 醫院藥房
    • 零售藥局
    • 網路藥局

第11章：膿皰瘡治療市場：依地域分類

  • 介紹
  • 北美洲
    • 概述
    • 北美主要製造商
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲主要製造商
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • その他
  • 亞太地區
    • 概述
    • 亞太地區主要製造商
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • その他
  • 拉丁美洲
    • 概述
    • 拉丁美洲主要製造商
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • その他
  • 中東和非洲（MEA）
    • 概述
    • 中東和非洲的主要製造商
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • その他

第12章：主要供應商分析：膿皰瘡治療產業

  • 競爭基準化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司簡介
    • GlaxoSmithKline plc
    • Ranbaxy Laboratories Limited
    • Roche Holding AG
    • Karalex Pharma, LLC
    • Teva Pharmaceutical Industries Ltd
    • Pfizer, Inc
    • SANDOZ GmbH
    • NovaBay Pharmaceuticals, Inc.
    • Lupin Limited
    • Leo Pharma A/S
    • Taro Pharmaceutical Industries Ltd
    • Others

第13章：360度AnalystView

簡介目錄
Product Code: ANV5842

Impetigo Treatment Market size was valued at US$ 778 Million in 2024, expanding at a CAGR of 5.8% from 2025 to 2032.

The Impetigo Treatment Market includes pharmaceuticals, topical antibiotics, antiseptics, and advanced dermatology solutions for treating impetigo, a contagious bacterial skin infection that primarily affects children. The rising prevalence of skin infections linked to poor hygiene, overcrowding, and increased bacterial resistance is a major driver of market growth. A key market trend is the shift toward non-antibiotic and antiseptic-based therapies, which reflect global efforts to combat antimicrobial resistance. However, the market faces a significant challenge in the form of rising MRSA (methicillin-resistant Staphylococcus aureus) infections, which reduce the efficacy of conventional antibiotics and complicate treatment protocols. Despite this, significant opportunities arise from innovation in combination therapies, novel topical formulations, and faster-acting antimicrobial agents, allowing for more targeted and resistant-free treatment options. Together, these factors position the impetigo treatment market for steady growth as healthcare systems prioritize skin infection control and more effective antimicrobial use.

Impetigo Treatment Market- Market Dynamics

Rising Focus on Advanced Dermatology and Infectious Disease Management

The rise in antibiotic resistance and skin infection prevalence is a major driver of the Impetigo Treatment Market. To ensure successful treatment outcomes, healthcare systems are prioritizing faster diagnostics, improved formulations, and advanced antimicrobial solutions. This trend is bolstered by strategic industry developments that increase research capacity. For example, in January 2020, Novartis' acquisition of The Medicines Company significantly strengthened its therapeutic pipeline and demonstrated the industry's commitment to developing infectious disease solutions. Although the acquisition focused on inclisiran, it reflects a larger push toward high-innovation portfolios, indirectly accelerating progress in dermatology and skin-infection therapeutics, including impetigo.

Impetigo Treatment Market- Segmentation Analysis:

The Global Impetigo Treatment Market is segmented by Route of Administration, Patient Type, Drug Class, Distribution Channel and Region.

According to the Route of Administration, the oral segment is important in the Impetigo Treatment Market because it works well for moderate to severe infections, recurrent cases, and situations where topical antibiotics fail. Oral formulations such as amoxicillin-clavulanate, clindamycin, and macrolides have systemic action, which aids in the elimination of deeper or widespread infections. Growing antimicrobial innovation and combination therapies also contribute to this segment's demand. In March 2020, Menlo Therapeutics' merger with Foamix Pharmaceuticals strengthened its dermatology portfolio, indirectly supporting improved antibiotic and anti-infective therapy development for skin diseases such as impetigo. Such strategic alliances strengthen R&D capabilities for more potent oral formulations, propelling this segment forward.

By Distribution Channel, the hospital pharmacy segment remains critical as hospitals treat more severe, rapidly spreading, or immunocompromised impetigo cases that necessitate prompt access to validated medications. This segment benefits from structured antibiotic stewardship, specialist consultations, and access to advanced diagnostics. The increase in hospital-based dermatology services and outbreak management protocols is also driving the segment. For instance, in November 2021, NovaBay Pharmaceuticals' acquisition of DERMAdoctor expanded the company's dermatology-focused product distribution through professional channels, including hospitals. Such corporate moves increase the availability of dermatologist-recommended formulations in hospital pharmacies, thereby improving patient access to reliable impetigo treatment options.

Impetigo Treatment Market- Geographical Insights

North America commands the Impetigo Treatment Market, owing to the high prevalence of bacterial skin infections and widespread public awareness of impetigo, particularly among children. The region has an advanced healthcare infrastructure, widespread access to dermatologists, and well-established reimbursement systems. In addition, strong government-backed public health programs and widespread availability of both branded and generic prescription medications have accelerated market adoption. A high level of healthcare spending, routine clinical screenings, and rapid diagnostic capabilities all help to detect impetigo cases early and treat them effectively. Additionally, the active involvement of major pharmaceutical companies in dermatology R&D, particularly in the fight against antibiotic resistance, reinforces North America's market leadership.

United States Impetigo Treatment Market- Country Insights

The United States is one of the most influential markets for impetigo treatment, thanks to a robust healthcare infrastructure, high infection awareness, and widespread access to dermatology services. The country experiences a consistent incidence of bacterial skin infections, particularly among children, fueling ongoing demand for topical and oral antibiotics. In addition, the United States prioritizes early diagnosis through routine pediatric screenings, which allows for timely and effective treatment. Strong pharmaceutical innovation, backed up by advanced R&D capabilities and streamlined regulatory pathways, shapes the market even further.

For example, in June 2025, Sanofi received FDA approval for Dupixent (dupilumab) to treat bullous pemphigoid, an inflammatory skin disease. Although not a direct impetigo treatment, this milestone highlights the nation's growing dermatology innovation landscape, opening up new avenues for managing associated skin infections and improving long-term patient outcomes.

Impetigo Treatment Market- Competitive Landscape:

The competitive landscape of the impetigo treatment market is distinguished by the presence of several key players involved in the development, manufacturing, and marketing of antibiotics and other treatment options. Companies are focusing on strategic initiatives like mergers and acquisitions, partnerships, and collaborations to improve their market position and product portfolio. Many companies prioritize the development of new antibiotic formulations and combination therapies as a means of addressing antibiotic resistance and improving treatment outcomes. For instance, in January 2022, Pfizer received approval for CIBINQO (abrocitinib), an oral inhibitor for the treatment of patients with moderate to severe dermatitis. CIBINQO will be an important new oral option for those who have yet to find relief. CIBINQO demonstrated good efficacy in clearing skin, reducing itching, and managing the severity and scope of eczema, with a benefit-risk profile that supports its use in the FDA-approved patient population.

Recent Developments:

In May 2024, NovaBay Pharmaceuticals has launched a dermatology service via telehealth for remote consultation and prescription to treat impetigo. The online service improves access, particularly in rural and underserved markets, by allowing clinicians to diagnose and treat impetigo remotely. The service is part of a trend toward hybrid dermatologic treatment models and allows patients to easily access topically prescribed antibiotics.

In June 2025, Ferrer announced the successful completion of its Phase III trial of Ozenoxacin 1% cream to treat impetigo in pediatric and adult patients, which demonstrated improved clinical and bacteriological responses compared to placebo. The cream showed early improvement on days 3-4 and was well tolerated in geographically dispersed centers in the United States, Germany, South Africa, and Ukraine. With this success, Ozenoxacin moves to the forefront of the near-term global market presence.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as following:

GLOBAL IMPETIGO TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • GlaxoSmithKline plc
  • Ranbaxy Laboratories Limited
  • Roche Holding AG
  • Karalex Pharma, LLC
  • Teva Pharmaceutical Industries Ltd
  • Pfizer, Inc
  • SANDOZ GmbH
  • NovaBay Pharmaceuticals, Inc.
  • Lupin Limited
  • Leo Pharma A/S
  • Taro Pharmaceutical Industries Ltd
  • Others

GLOBAL IMPETIGO TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Topical
  • Oral

GLOBAL IMPETIGO TREATMENT MARKET, BY PATIENT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Children
  • Elderly
  • Adults

GLOBAL IMPETIGO TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Cephalosporins
  • Quinolones
  • Sulfonamides
  • Fusidane
  • Lincosamide
  • Penicillin
  • Tetracycline
  • Others

GLOBAL IMPETIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL IMPETIGO TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Impetigo Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Impetigo Treatment Market Snippet by Route of Administration
    • 2.1.2. Impetigo Treatment Market Snippet by Patient Type
    • 2.1.3. Impetigo Treatment Market Snippet by Drug Class
    • 2.1.4. Impetigo Treatment Market Snippet by Distribution Channel
    • 2.1.5. Impetigo Treatment Market Snippet by Country
    • 2.1.6. Impetigo Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Impetigo Treatment Key Market Trends

  • 3.1. Impetigo Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Impetigo Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Impetigo Treatment Market Opportunities
  • 3.4. Impetigo Treatment Market Future Trends

4. Impetigo Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Impetigo Treatment Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Impetigo Treatment Market Landscape

  • 6.1. Impetigo Treatment Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Impetigo Treatment Market - By Route of Administration

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 7.1.2. Topical
    • 7.1.3. Oral

8. Impetigo Treatment Market - By Patient Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Patient Type, 2024 & 2032 (%)
    • 8.1.2. Children
    • 8.1.3. Elderly
    • 8.1.4. Adults

9. Impetigo Treatment Market - By Drug Class

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
    • 9.1.2. Cephalosporins
    • 9.1.3. Quinolones
    • 9.1.4. Sulfonamides
    • 9.1.5. Fusidane
    • 9.1.6. Lincosamide
    • 9.1.7. Penicillin
    • 9.1.8. Tetracycline
    • 9.1.9. Others

10. Impetigo Treatment Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Patient Type, 2024 & 2032 (%)
    • 10.1.2. Hospital Pharmacies
    • 10.1.3. Retail Pharmacies
    • 10.1.4. Online Pharmacies

11. Impetigo Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Impetigo Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Impetigo Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Impetigo Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Impetigo Treatment Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Impetigo Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Impetigo Treatment Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. GlaxoSmithKline plc
    • 12.2.2. Ranbaxy Laboratories Limited
    • 12.2.3. Roche Holding AG
    • 12.2.4. Karalex Pharma, LLC
    • 12.2.5. Teva Pharmaceutical Industries Ltd
    • 12.2.6. Pfizer, Inc
    • 12.2.7. SANDOZ GmbH
    • 12.2.8. NovaBay Pharmaceuticals, Inc.
    • 12.2.9. Lupin Limited
    • 12.2.10. Leo Pharma A/S
    • 12.2.11. Taro Pharmaceutical Industries Ltd
    • 12.2.12. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us